Metformin: safety in cardiac patients

@article{Khurana2010MetforminSI,
  title={Metformin: safety in cardiac patients},
  author={Rohit Khurana and Iqbal S. Malik},
  journal={Postgraduate Medical Journal},
  year={2010},
  volume={86},
  pages={371 - 373}
}
Metformin is a biguanide, insulin sensitiser that reduces blood sugar levels. There are concerns about the risk of lactic acidosis in patients receiving metformin who have procedures requiring iodinated contrast, and in those with renal impairment or heart failure. The data on which these concerns are based are reviewed, with the conclusion that metformin treatment is rarely to blame for lactic acidosis. A generic policy of stopping metformin 48 h before and 48 h after the procedure in all… Expand
Metformin and heart failure: never say never again
TLDR
Although longer follow-up data and more explicit information about the situation in patients with very advanced HF are needed, the cardiac safety of metformin has profound clinical implications and may be anticipated to further encourage its widespread use. Expand
[Severe lactic acidosis due to metformin: report of 3 cases].
TLDR
Three cases in which the toxic origin of acidosis has been objectified by the plasma assay and intra-erythrocyte metformin are reported, requiring compliance with the cons-indications and rules of prescription of this drug. Expand
Discontinuation of metformin in the setting of coronary angiography: clinical uncertainty amongst physicians reflecting a poor evidence base.
  • A. Maznyczka, A. Myat, A. Gershlick
  • Medicine
  • EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • 2012
TLDR
Evidence for M-ALA in diabetics on metformin undergoing coronary intervention is lacking and existing guidance on the management of such patients is inconsistent, and more robust evidence is needed in the form of a large, adequately-sized randomised trial or extensive registry to optimally manage those patients requiring contrast-based coronary interventions. Expand
Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients.
TLDR
The results of this study indicate a relatively good tolerability of metformin by patients with the traditional contraindications to this drug, which supports other authors' suggestion that indications and contrainDications to meetformin should be re-evaluated. Expand
Safety of diabetes drugs in patients with heart failure.
TLDR
A review of the available evidence on the safety of diabetes drugs in HF, focused on the main observational and experimental studies, helps understand the neutrality, risks and potential benefits of these agents. Expand
Pharmacokinetics of a Fixed-Dose Combination of Atorvastatin and Metformin Extended Release versus Concurrent Administration of Individual Formulations
TLDR
Atorvastatin/metformin ER 10 mg/500 mg FDC tablets can be used safely in clinical settings to decrease the pill burden and increase patient compliance with therapy. Expand
Metformin Used for Weight Loss by Non-Diabetic Sudanese Females
TLDR
It is concluded that women who used Metformin over the counter had a good experience with it especially when combined with diet and exercise. Expand
Is it necessary to discontinue metformin in diabetic patients with GFR > 60 ml/min per 1.73 m2 undergoing coronary angiography: A controversy still exists?
TLDR
The results of the present study indicate that metformin continuation in diabetic patients with a GFR of more than 60 ml/min per 1.73 m2 undergoing coronary angiography does not enhance the risk of MALA development. Expand
Cardiovascular outcomes of antidiabetic drugs
TLDR
The current review summarizes the results of the main trials focused on the cardiovascular outcomes of traditional as well as newer antidiabetic drugs. Expand
Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients Without Diabetes Presenting with ST-elevation Myocardial Infarction: Data from the GIPS-III Trial
TLDR
It is concluded that initiation of metformin shortly after primary PCI has no adverse effect on renal function in patients without diabetes or prior renal impairment, further providing evidence of the safety of meetformin use after myocardial infarction and subsequent contrast exposure. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
TLDR
There is no evidence from prospective comparative trials or from observational cohort studies that metformin is associated with an increased risk of lactic acidosis, or with increased levels of lactate, compared to other anti-hyperglycemic treatments if prescribed under the study conditions. Expand
Metformin and contrast media--a dangerous combination?
TLDR
A systematic review of the literature has shown that almost all reported cases of MALA following i.v. contrast medium occurred where there was either pre-existing poor renal function or another contraindication to metformin usage. Expand
Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media
TLDR
No conclusive evidence was found to indicate that the intravascular use of contrast media precipitated the development of metformin-induced lactic acidosis in patients with normal S-creatinine. Expand
Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality
TLDR
There does not appear to be clinical uncertainty with regards to the safety or effectiveness of metformin in HF making a definitive randomized trial virtually impossible. Expand
Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy.
TLDR
Many patients are treated with metformin despite having clinical conditions that place them at risk for developing lactic acidosis, and it is essential that prescribers develop a better understanding of the prescribing guidelines for met formin. Expand
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?
Many patients with type 2 diabetes are denied treatment with metformin because of “contraindications” such as cardiac failure, which may not be absolute contraindications
Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations.
TLDR
Observations suggest that accumulation of metformin may not be as significant with respect to high arterial levels of lactate and their effects as has been traditionally thought. Expand
Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study
TLDR
It is suggested that thiazolidinediones and metformin are not associated with increased mortality and may improve outcomes in older patients with diabetes and heart failure and Randomized trials are warranted to corroborate these findings. Expand
Metformin's contraindications should be contraindicated
TLDR
There is now evidence that the drug Metformin decreases the risk of morbidity and death when used to treat type 2 diabetes.[2][2] However, concern remains. Expand
Insulin Therapy in Phenformin-Associated Lactic Acidosis: A Case Report, Biochemical Considerations and Review of the Literature
TLDR
A patient with phenformin-associated lactic acidosis was treated with insulin and showed marked improvement coincident with the expected onset of action of the insulin administered, and insulin administration may thus constitute specific therapy. Expand
...
1
2
3
4
...